FOLH1 and prostate carcinoma: In vitro and in vivo animal models suggest that treatment with histone deacetylase inhibitors may reverse these epigenetic changes in prostate cancer cells and restore PSMA expression, which in vivo could be readily monitored using PSMA-targeted PET/CT imaging.